| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.18▼ | 4.16▼ | 4.16▼ | 4.08▲ | 4.10▲ |
| MA10 | 4.17▼ | 4.16▼ | 4.17▼ | 3.93▲ | 4.80▼ |
| MA20 | 4.16▼ | 4.20▼ | 4.13▲ | 4.03▲ | 5.28▼ |
| MA50 | 4.16▼ | 4.10▲ | 4.02▲ | 4.90▼ | 6.99▼ |
| MA100 | 4.19▼ | 3.99▲ | 3.93▲ | 5.38▼ | 5.94▼ |
| MA200 | 4.16▼ | 3.97▲ | 4.20▼ | 7.04▼ | 6.96▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.016▼ | -0.011▼ | 0.088▲ | -0.102▼ |
| RSI | 39.977▼ | 47.532▼ | 51.794▲ | 45.856▼ | 38.660▼ |
| STOCH | 67.513 | 19.618▼ | 20.052 | 67.932 | 10.123▼ |
| WILL %R | -90.000▼ | -90.625▼ | -90.625▼ | -34.857 | -82.435▼ |
| CCI | -101.218▼ | -46.280 | -68.377 | 116.213▲ | -83.711 |
|
Thursday, June 18, 2026 01:42 PM
A focused review of Verastem, a clinical-stage oncology company shaped by trial data, regulatory milestones, funding needs, and biotech market volatility.
|
|
Wednesday, June 17, 2026 04:30 AM
Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma ...
|
|
Wednesday, June 17, 2026 04:30 AM
Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/06/26 | 4.24 | 4.425 | 4.11 | 4.12 | 4,765,353 |
| 17/06/26 | 4.09 | 4.40 | 4.09 | 4.17 | 2,499,635 |
| 16/06/26 | 4.01 | 4.10 | 3.85 | 4.01 | 1,509,772 |
| 15/06/26 | 4.16 | 4.19 | 3.93 | 4.00 | 1,984,735 |
| 12/06/26 | 3.94 | 4.18 | 3.94 | 4.10 | 1,599,863 |
| 11/06/26 | 3.76 | 4.00 | 3.68 | 3.94 | 1,523,790 |
| 10/06/26 | 3.77 | 3.975 | 3.74 | 3.76 | 2,189,058 |
| 09/06/26 | 3.75 | 3.855 | 3.55 | 3.82 | 3,039,045 |
| 08/06/26 | 3.80 | 3.85 | 3.62 | 3.67 | 1,865,865 |
| 05/06/26 | 3.90 | 3.91 | 3.69 | 3.71 | 3,028,030 |
|
|
||||
|
|
||||
|
|